Overview
Trigeminal neuralgia is a facial-pain disorder marked by sudden, severe, electric-shock-like attacks in one or more divisions of the trigeminal nerve. Attacks are usually unilateral, last from a fraction of a second to about two minutes, and may be triggered by light touch, chewing, brushing teeth, talking, shaving, or a breeze. Between attacks, some people are pain-free; others have a continuous background ache or burning pain.12
Trigeminal neuralgia is treatable, but it is often misdiagnosed as a dental, sinus, jaw-joint, or migraine problem. A careful neurological history and examination—and usually high-quality MRI—are important because treatment depends on whether the condition is classical, idiopathic, or secondary to another disorder.23
The most important points for patients in 2026 are:
- Diagnosis is clinical, supported by imaging. There is no blood test that confirms trigeminal neuralgia. MRI is used to look for neurovascular compression and secondary causes such as multiple sclerosis or a tumor.2
- Carbamazepine and oxcarbazepine remain the best-established first-line medicines. Their benefits must be balanced against dizziness, sleepiness, low sodium, drug interactions, liver or blood-count abnormalities, and rare severe skin reactions.24
- Procedures are not all equivalent. Microvascular decompression, percutaneous procedures, and stereotactic radiosurgery have different goals, durability, risks, and effects on facial sensation.34
- Botulinum toxin is an off-label option with limited evidence. It may help selected patients who cannot tolerate or do not respond to standard medication, but long-term comparative evidence is incomplete.5
- New or atypical facial pain deserves reassessment. Persistent numbness, hearing change, bilateral symptoms, weakness, a young age at onset, or a pain pattern that does not fit classic brief triggered attacks increases concern for another cause.
Evidence cutoff: This article reflects publicly available evidence through July 10, 2026. Treatment decisions should be individualized with a clinician experienced in facial pain.
What Trigeminal Neuralgia Feels Like
The trigeminal nerve carries sensation from the face and supplies muscles used for chewing. It has three main divisions:
- V1 (ophthalmic): forehead, scalp, upper eyelid, and eye region
- V2 (maxillary): cheek, upper lip, upper teeth, and side of the nose
- V3 (mandibular): lower jaw, lower lip, lower teeth, and part of the tongue
Classic attacks are abrupt, intense, and stereotyped. The pain is often described as an electric shock, stabbing, lightning bolt, or hot needle. A series of attacks may cluster over minutes or hours, and active periods can alternate with remissions lasting weeks or longer. V2 and V3 are affected more often than V1.13
A brief refractory period—when the same trigger does not immediately provoke another attack—can occur after a paroxysm. Some patients develop a continuous background pain in the same distribution. That does not automatically exclude trigeminal neuralgia, but it can predict a more difficult course and broadens the differential diagnosis.
Three Etiologic Categories
| Category | Meaning | Typical implication |
|---|---|---|
| Classical | A blood vessel compresses the trigeminal root with associated nerve distortion or atrophy—not merely incidental contact. | Microvascular decompression may be considered when medication is ineffective or poorly tolerated. |
| Secondary | Another condition explains the neuralgia, such as multiple sclerosis, a cerebellopontine-angle mass, or another structural lesion. | Treatment addresses both the neuralgia and the underlying disorder. |
| Idiopathic | No definite neurovascular compression with morphological change and no secondary cause is found. | Medication and selected procedures may still be effective. |
Simple vessel-to-nerve contact is common even in people without facial pain. The imaging finding is most meaningful when it matches the painful side and shows morphological nerve change.23
How Trigeminal Neuralgia Is Diagnosed
History and examination
The diagnosis starts with the exact location, quality, duration, triggers, frequency, and neurological findings. The clinician also asks about dental procedures, facial trauma, rash, hearing symptoms, migraine features, jaw dysfunction, autonomic symptoms, numbness, and medication response.
MRI
The EAN guideline recommends MRI as part of the workup because clinical features alone cannot reliably exclude secondary trigeminal neuralgia. Ideally, the study includes thin-section, high-resolution sequences through the trigeminal nerve and posterior fossa, often combined with vascular imaging. Contrast may be appropriate depending on the clinical question.2
MRI may identify neurovascular compression, demyelination from multiple sclerosis, tumor, inflammation, or another lesion. A normal MRI does not invalidate an otherwise typical clinical diagnosis.
When the pattern is atypical
- Facial sensory loss or corneal-reflex change
- Bilateral pain
- Prominent hearing loss, vertigo, or other cranial-nerve deficits
- Onset at a younger age, especially with other neurological symptoms
- Pain that is continuously burning without brief triggered shocks
- Autonomic features such as marked tearing or nasal congestion with longer attacks
- Persistent oral or dental pain that does not follow a trigeminal division
These findings may point toward painful trigeminal neuropathy, persistent idiopathic facial pain, dental disease, temporomandibular disorder, migraine, cluster headache, postherpetic neuralgia, glossopharyngeal neuralgia, or another diagnosis.6
Medication Treatment
Carbamazepine and oxcarbazepine
These sodium-channel-blocking antiseizure medicines remain first-line. Doses are usually started low and increased according to response and tolerability. Pain control can be dramatic, which supports—but does not prove—the diagnosis.24
Important safety issues include dizziness, imbalance, double vision, sedation, nausea, low sodium, liver abnormalities, low blood counts, drug interactions, and rare severe skin reactions. Clinicians may monitor sodium, blood counts, and liver tests. Carbamazepine can reduce the effectiveness of many medications, including some anticoagulants and hormonal contraceptives. Genetic screening for HLA-B*15:02 is recommended in certain ancestry groups before carbamazepine because of increased risk of Stevens–Johnson syndrome or toxic epidermal necrolysis.
Other medicines
Lamotrigine, baclofen, gabapentin, pregabalin, and other agents may be used alone or as add-on therapy when first-line drugs are inadequate or not tolerated. Evidence is generally weaker than for carbamazepine or oxcarbazepine. Opioids usually perform poorly for the brief, high-intensity paroxysms and carry substantial harms.23
Severe acute exacerbations
When a person cannot eat, drink, speak, or take oral medication because of relentless attacks, urgent specialist or hospital treatment may be needed. Intravenous fosphenytoin/phenytoin or lidocaine is sometimes used as short-term rescue under monitoring, but evidence is limited and these are not routine home treatments.23
Procedures When Medication Is Not Enough
Microvascular decompression
Microvascular decompression separates an offending vessel from the trigeminal nerve through posterior-fossa surgery. It offers the best chance of durable pain freedom for appropriate patients with classical trigeminal neuralgia and aims to preserve facial sensation. It requires general anesthesia and craniotomy and carries risks including hearing loss, cerebrospinal-fluid leak, stroke, infection, facial weakness or numbness, anesthesia complications, and rare death.24
Percutaneous procedures
Radiofrequency thermocoagulation, balloon compression, and glycerol rhizolysis injure selected trigeminal fibers to interrupt pain. They can provide rapid relief and may be appropriate for older or medically frail patients, or when microvascular decompression is not desired. Facial numbness is expected to varying degrees; painful dysesthesia, corneal numbness, chewing weakness, recurrence, and anesthesia dolorosa are potential complications.
Stereotactic radiosurgery
Focused radiation is delivered to the trigeminal root without an incision. Relief is often delayed for weeks or months, recurrence can occur, and facial numbness is a relevant trade-off. It may be considered when open surgery is not suitable.
Botulinum toxin
Small randomized trials and reviews suggest that subcutaneous or intradermal botulinum toxin type A injections may reduce attacks in some patients, but protocols vary and evidence remains limited. It is not an FDA-approved trigeminal-neuralgia treatment. Temporary facial weakness or asymmetry can occur.5
Urgent and Emergency Situations
Seek urgent assessment for facial pain accompanied by a new neurological deficit, vision loss, vesicular rash near the eye, fever, altered mental status, severe new headache, trauma, progressive numbness, difficulty swallowing, or inability to maintain hydration or nutrition. New facial weakness is not a typical feature of isolated trigeminal neuralgia.
Severe pain can produce depression, fear of eating, weight loss, and suicidal thoughts. Immediate crisis support or emergency care is appropriate when safety is at risk.
A Practical Treatment Framework
- Confirm the phenotype. Brief, triggered, unilateral electric-shock attacks are the core pattern.
- Obtain appropriate imaging. Identify classical neurovascular compression and exclude secondary causes.
- Start evidence-based medication. Use carbamazepine or oxcarbazepine when appropriate, with safety monitoring.
- Do not wait indefinitely when medication fails. Early neurosurgical consultation allows patients to compare procedures before disability and medication toxicity become severe.
- Reassess the diagnosis when the course changes. Continuous pain, numbness, bilateral symptoms, or new deficits deserve renewed evaluation.
Bottom line: trigeminal neuralgia is a clinical diagnosis with several distinct causes. The most effective plan matches the pain pattern, MRI findings, medical risks, and patient preferences rather than treating every form of facial pain the same way.
At Los Altos Neurology, evaluation focuses on confirming the facial-pain syndrome, reviewing high-resolution imaging, selecting medication safely, and coordinating referral for procedural treatment when appropriate.
References
- International Headache Society. International Classification of Headache Disorders, 3rd edition. ICHD-3: Trigeminal neuralgia.
- Bendtsen L, Zakrzewska JM, Abbott J, et al. Eur J Neurol. 2019;26:831-849. doi:10.1111/ene.13950. European Academy of Neurology guideline on trigeminal neuralgia.
- Lambru G, Zakrzewska J, Matharu M. Pract Neurol. 2021;21:392-402. Trigeminal neuralgia: a practical guide.
- Royal College of Surgeons of England, Faculty of Dental Surgery. 2021. Guidelines for the management of trigeminal neuralgia.
- Rubis A, Juodzbalys G. Clin J Pain. 2024;40:293-303. Botulinum toxin type A for trigeminal neuralgia: systematic review.
- Miller JP, Acar F, Burchiel KJ. Continuum. 2021;27:665-685. Cranial neuralgias: differential diagnosis and management.
Medical disclaimer. This article is provided for general educational and informational purposes only. It does not constitute individualized medical advice, diagnosis, treatment, a recommendation for any specific test or therapy, or informed consent. Medical information changes over time, and this article may not reflect developments occurring after its stated review date or apply to your individual circumstances. Do not disregard or delay professional medical advice, or start, stop, or change any medication or treatment, based on this article. Discuss personal medical decisions with a qualified healthcare professional who can evaluate your individual history and circumstances. Accessing or using this website does not, by itself, create a physician–patient relationship with Los Altos Neurology or any of its clinicians. Do not use this website for urgent or emergency medical concerns; call 911 or seek immediate emergency care. Although Los Altos Neurology makes reasonable efforts to provide accurate and current information, it does not guarantee that all content is complete, current, or applicable to every individual. See our full Medical Disclaimer.